Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
23 results
- ALTTOIndependent statistical analysis of the phase 3 ALTTO trial of lapatinib and trastuzumab in breast neoplasms, covering randomized trial design, disease-free survival, overall survival, recurrence endpoints, safety, and time-to-event methodology.
- BRIM-3Independent statistical analysis of the randomized phase 3 BRIM-3 trial of vemurafenib versus dacarbazine in previously untreated patients with metastatic melanoma, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- EMPEROR-PreservedA detailed statistical analysis of EMPEROR-Preserved, the randomized phase 3 trial of 10 mg empagliflozin versus placebo in patients with heart failure, including time-to-event outcomes, Cox models, recurrent-event analysis, MMRM, and interpretation.
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FLOWIndependent statistical analysis of the FLOW phase 3 trial of semaglutide versus placebo in people with type 2 diabetes and chronic kidney disease, including trial design, the composite renal endpoint, Cox proportional-hazards…
- GS-US-236-0102Independent statistical analysis of GS-US-236-0102, a randomized phase 3 trial comparing Stribild with Atripla in antiretroviral treatment-naive adults with HIV-1 infection, including the Week 48 virologic-success endpoint, non-inferiority framework, Wald/z-test methodology, and…
- GS-US-236-0103Independent statistical analysis of GS-US-236-0103 (NCT01106586), a randomized phase 3 study comparing Stribild with ritonavir-boosted atazanavir plus Truvada in antiretroviral treatment-naive adults with HIV-1.
- HIMALAYAComplete statistical analysis of the phase 3 HIMALAYA trial of durvalumab and tremelimumab in advanced hepatocellular carcinoma, including trial design, overall survival, non-inferiority methodology, Cox regression, log-rank testing, and interpretation.
- HPTN 083Independent statistical analysis of HPTN 083, a randomized phase 2/3 trial comparing injectable cabotegravir with TDF/FTC for HIV pre-exposure prophylaxis in HIV-uninfected men and transgender women who have sex with men.
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- METEORIndependent statistical analysis of the METEOR phase 3 trial of cabozantinib versus everolimus in metastatic renal cell carcinoma, including progression-free survival, overall survival, objective response rate, trial design, and statistical methodology.
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SOPHIAIndependent statistical analysis of the SOPHIA phase 3 trial of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer, including its randomized design, time-to-event endpoints, hazard ratios, confidence intervals,…
- SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.
- VELOURIndependent statistical analysis of the phase 3 VELOUR trial of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in metastatic colorectal cancer after failure of an oxaliplatin-based regimen, including trial design, survival analysis,…
- ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…